No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac DiseaseJoseph A. Murray, Richard A. Krause, Daniel C. Adelman et al.|Gastroenterology|2016Cited by 137
Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group studyChristophe Cellier, Ralph Raymond, Gerd Bouma et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 101
O38 Coeliac disease outcomes of budesonide response in adults: COBRA STUDY from the European society for the study of coeliac disease (ESsCD)Suneil Raju, D S Sanders, Flora Kokwaro et al.|Unknown|2026Cited by 0